MARKET

KNSA

KNSA

Kiniksa Pharmaceuticals International, plc
NASDAQ
96.28
+0.52
+0.54%
Pre Market: 96.30 +0.02 +0.02% 04:00 11/13 EST
OPEN
95.85
PREV CLOSE
95.76
HIGH
96.67
LOW
94.32
VOLUME
6
TURNOVER
0
52 WEEK HIGH
99.31
52 WEEK LOW
37.02
MARKET CAP
7.56B
P/E (TTM)
73.50
1D
5D
1M
3M
1Y
5Y
1D
Kiniksa Stock In Focus After Stronger Earnings Per Share
Simply Wall St · 3d ago
Weekly Report: what happened at KNSA last week (1102-1106)?
Weekly Report · 3d ago
Is Kiniksa Pharmaceuticals International (KNSA) Undervalued As Earnings Per Share Keeps Improving?
Simply Wall St · 4d ago
The Bet Behind Kiniksa’s 123% Run
Simply Wall St · 5d ago
Kiniksa Pharmaceuticals International Average Price Target Raised 13.15% to $111.62
NASDAQ · 11/02 21:48
Kiniksa Stock In Focus After Earnings Beat
Simply Wall St · 11/02 12:26
Weekly Report: what happened at KNSA last week (1026-1030)?
Weekly Report · 11/02 09:34
Why Kiniksa Pharmaceuticals International (KNSA) Moved Today
Simply Wall St · 11/01 11:38
More
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

Webull offers Kiniksa Pharmaceuticals Internatinl, PLC stock information, including NASDAQ: KNSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KNSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KNSA stock methods without spending real money on the virtual paper trading platform.